Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, ...

IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

Antibiotics are one of the most common medicines in the world, with about 236 million prescriptions in the U.S. | The company ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Remedee Labs, a startup based in Paris, France, has received a European approval for its device-based approach to treating ...

After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient ...

A bipolar disorder research initiative backed by Big Tech has announced $36 million in new funding for research into the ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...